{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.17","upperLimit":"15.44","value":"8.31"},{"groupId":"OG001","lowerLimit":"2.69","upperLimit":"24.94","value":"24.94"},{"comment":"NA: not estimable due to the insufficient number of participants with events","groupId":"OG002","lowerLimit":"4.17","upperLimit":"NA","value":"9.66"},{"groupId":"OG003","lowerLimit":"4.17","upperLimit":"4.21","value":"4.19"},{"groupId":"OG004","lowerLimit":"5.55","upperLimit":"12.98","value":"9.72"},{"groupId":"OG005","lowerLimit":"2.56","upperLimit":"14.26","value":"7.54"},{"groupId":"OG006","lowerLimit":"5.55","upperLimit":"38.67","value":"12.58"},{"groupId":"OG008","lowerLimit":"4.17","upperLimit":"27.60","value":"9.05"},{"comment":"NA: not estimable due to the insufficient number of participants with events","groupId":"OG009","lowerLimit":"8.34","upperLimit":"NA","value":"16.59"},{"groupId":"OG010","lowerLimit":"5.62","upperLimit":"12.98","value":"9.72"},{"groupId":"OG011","lowerLimit":"8.41","upperLimit":"22.11","value":"16.59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"19"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"16"},{"groupId":"OG009","value":"22"},{"groupId":"OG010","value":"44"},{"groupId":"OG011","value":"41"}],"units":"Participants"}],"description":"Time from the date of the first documented CR or PR by BIRC per RECIST 1.1 to the first documented progression or date of death due to any cause for patients with confirmed PR or CR. The Kaplan-Meier method was used to estimate DOR, and the median DOR, along with 95% confidence intervals was reported. If a subject did not have an event, DOR was censored at the date of last adequate tumor assessment.\n\nCR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG000","title":"Cohort 1a: Pre-treated Patients With MET GCN ≥ 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 6 and \\< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)","id":"OG001","title":"Cohort 1b: Pre-treated Patients With MET GCN ≥ 6 and < 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 4 and \\< 6 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG002","title":"Cohort 2: Pre-treated Patients With MET GCN ≥ 4 and < 6 (2/3L)"},{"description":"Pre-treated patients with MET GCN \\< 4 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG003","title":"Cohort 3: Pre-treated Patients With MET GCN < 4 (2/3L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG004","title":"Cohort 4: Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)","id":"OG005","title":"Cohort 5a: Treatment-naïve Patients With MET GCN ≥10 (1L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)","id":"OG006","title":"Cohort 5b: Treatment-naïve Patients With MET Mutation Regardless of MET GCN (1L)"},{"description":"Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)","id":"OG007","title":"Cohort 6.1 (Expansion of Cohort 1a): Pre-treated Patients MET GCN ≥ 10 Without MET Mutation (2L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)","id":"OG008","title":"Cohort 6.2 (Expansion of Cohort 4): Pre-treated Patients With MET Mutation (2L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)","id":"OG009","title":"Cohort 7 (Expansion of Cohort 5b): Treatment-naïve With MET Mutation Regardless of MET GCN (1L)"},{"description":"All pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L). (Participants from Cohort 4 and Cohort 6.2)","id":"OG010","title":"Cohort 4 + Cohort 6.2: All Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"All treatment naive patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as first line (1L) (Participants from Cohort 5b and Cohort 7)","id":"OG011","title":"Cohort 5b + Cohort 7: All Treatment-naive With MET Mutation Regardless of MET GCN (1L)"}],"paramType":"MEDIAN","populationDescription":"Participants with confirmed CR or PR by BIRC in FAS","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years","title":"Duration of Response (DOR) by BIRC Assessment","type":"SECONDARY","unitOfMeasure":"Months"}